StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca FX sensitivity: SEK impact on Core Operating Profit by Quarter

FX sensitivity (+5% vs USD): SEK impact on Core Operating Profit ($M) ($M)

AstraZeneca FX sensitivity: SEK impact on Core Operating Profit: -$71M in Q2 2026, down 202.9% from a year earlier.

Latest, Q2 2026
-71
Period ended Jun 30, 2026
Change on a year earlier
-202.9%
69 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| SEK | | Operating expense | | 9.81 | | 9.25 | | 6 | | 9.50 | | 3 | | 9 | (71)”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Currency Sensitivity Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFX sensitivity (+5% vs USD): SEK impact on Core Operating Profit ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-71-202.9%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-71-202.9%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-71-202.9%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202569-209.5%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202569-209.5%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202569-209.5%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202469-209.5%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-63+14.5%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-63+14.5%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-63+14.5%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-63+14.5%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-55-32.9%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-55-32.9%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-55-32.9%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-55-32.9%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-82+39.0%Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca FX sensitivity: SEK impact on Core Operating Profit ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fx-sens-sek-op

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?